ArticleDiscover oncology2025
Machine learning modeling and analysis of prognostic hub genes in cervical adenocarcinoma: a multi target therapy for enhancement in immunosurveillance.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of gut microbiota dynamics and probiotic impact on HPV-associated head and neck cancer using 16S rRNA sequencing and cytokine profiling.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocervical adenocarcinoma (ECA) the fatal and intrusive subtype of cervical carcinoma is on rise from the last decade. Its improper detection leads to worst clinical outcomes that urges the discovery of novel biomarkers. Therefore, we proposed insilico and invitro based approches to identify key genes that could be used as potential targeted therapies. RNA-seq and gene expression data was operated via R-programming that identified 11,592 differential expressed genes which are mainly enriched in metabolic pathways, chemical carcinogenesis-receptor activation, amoebias, MAPK and PI3K-AKT signaling pathway. Clustering modules and hub genes were retrieved to design network of immune cells with varying expression using multiple statistical algorithms. The Drugs targeting hub genes were determined from Drug gene interaction database which was further categorized for docking and dynamics based simulations. Results indicate high binding affinity of Imatinib compound into active pockets of BIRC5 which is confirmed by cell viability lab experiment. Current study demonstrates novel biomarkers and therapeutic drugs for in depth understanding of endocervical carcinogensis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.